Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Optimal Rule-Out Biomarker Strategy Developed for Acute MI

By LabMedica International staff writers
Posted on 27 Sep 2016
Assessment of patients presenting to the Emergency Department (ED) with symptoms suggestive of acute coronary syndrome (ACS) represents a major clinical challenge, since the majority of patients do not have a final diagnosis of acute myocardial infarction (AMI).

A multi-marker strategy, combining high-sensitivity troponins (hs-cTn) with an early cardiac marker may improve sensitivity and increase the proportion of low-risk patients suitable for early discharge by allowing a higher troponin threshold to be utilized. More...
Heart Fatty Acid Binding Protein (H-FABP), a highly myocardium-specific protein and early rise marker of ACS, is a potential candidate.

Scientists at the University of Otago (Dunedin, New Zealand) and their medical colleagues enrolled consecutive patients presenting acutely to the emergency department (ED) with symptoms suggestive of AMI. Patient assessment included blood sampling for contemporary TnI (c-TnI) at presentation and six to 12 hours later. The primary end point was AMI during initial hospital attendance. AMI diagnosis was based on evidence of myocardial necrosis, together with clinical features consistent with myocardial ischemia (ischemic symptoms, ECG changes or imaging evidence).

Necrosis was diagnosed on the basis of a rising or falling pattern of the routine laboratory c-TnI (ARCHITECT c-TnI assay, Abbott Diagnostics, Lake Forest, IL, USA), with at least one value above 0.028 ng/mL. Hs-cTnI concentrations were measured on the ARCHITECT STAT platform. Hs-cTnT concentrations were measured with the Roche Elecsys hs-cTnT assay. H-FABP concentrations were measured with an immunoturbidimetric H-FABP assay on the ARCHITECT platform.

The team recruited 1,079 patients including 248 with AMI. H-FABP of less than 4.3ng/mL plus hs-cTnI of greater than 10.0 ng/L together with a negative ECG maintained more than 99% sensitivity for AMI whilst classifying 40.9% of patients as low-risk. The combination of H-FABP less than 3.9ng/mL and hs-cTnT of greater than 7.6ng/L with a negative ECG maintained the same sensitivity whilst classifying 32.1% of patients as low risk.

The authors concluded that in patients requiring rule-out of AMI, the addition of H-FABP to hs-cTn at presentation in the absence of new ischemic ECG findings may accelerate clinical diagnostic decision making by identifying up to 40% of such patients as low-risk for AMI on the basis of blood tests performed on presentation. If implemented this has the potential to significantly accelerate triaging of patients for early discharge from the ED. The study was published on August 31, 2016, in the journal BMC Emergency Medicine.

Related Links:
University of Otago
Abbott Diagnostics


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.